NO992116L - Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner - Google Patents

Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner

Info

Publication number
NO992116L
NO992116L NO992116A NO992116A NO992116L NO 992116 L NO992116 L NO 992116L NO 992116 A NO992116 A NO 992116A NO 992116 A NO992116 A NO 992116A NO 992116 L NO992116 L NO 992116L
Authority
NO
Norway
Prior art keywords
therapeutic
cytokines
diagnostic agents
signal transduction
present
Prior art date
Application number
NO992116A
Other languages
English (en)
Other versions
NO992116D0 (no
Inventor
Douglas J Hilton
Warren S Alexander
Elizabeth M Viney
Tracy A Willson
Rachael T Richardson
Robyn Starr
Sandra E Nicholson
Donald Metcalf
Nicos A Nicola
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO3384A external-priority patent/AUPO338496A0/en
Priority claimed from AUPO5117A external-priority patent/AUPO511797A0/en
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Publication of NO992116D0 publication Critical patent/NO992116D0/no
Publication of NO992116L publication Critical patent/NO992116L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
NO992116A 1996-11-01 1999-04-30 Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner NO992116L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO3384A AUPO338496A0 (en) 1996-11-01 1996-11-01 Therapeutic and diagnostic agents
AUPO5117A AUPO511797A0 (en) 1997-02-14 1997-02-14 Therapeutic and diagnostic agents-II
PCT/AU1997/000729 WO1998020023A1 (en) 1996-11-01 1997-10-31 Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines

Publications (2)

Publication Number Publication Date
NO992116D0 NO992116D0 (no) 1999-04-30
NO992116L true NO992116L (no) 1999-06-29

Family

ID=25645307

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992116A NO992116L (no) 1996-11-01 1999-04-30 Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner

Country Status (13)

Country Link
US (1) US20080166730A1 (no)
EP (2) EP1975234A2 (no)
JP (2) JP2001502183A (no)
KR (2) KR100719080B1 (no)
CN (2) CN1253565A (no)
AT (1) ATE398136T1 (no)
CA (1) CA2270171A1 (no)
DE (1) DE69738767D1 (no)
DK (1) DK0948522T3 (no)
ES (1) ES2308785T3 (no)
GB (1) GB2331753A (no)
NO (1) NO992116L (no)
WO (1) WO1998020023A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
CA2230986A1 (en) * 1997-05-07 1998-11-07 Smithkline Beecham Corporation Epo primary response gene 1, eprg1
WO1999003994A1 (en) * 1997-07-18 1999-01-28 Schering Corporation Suppressors of cytokine signaling socs16; related reagents
JP2001508312A (ja) * 1997-11-03 2001-06-26 インサイト・ファーマスーティカルズ・インコーポレイテッド サイトカインシグナリングのサプレッサ
AU2668699A (en) * 1998-02-11 1999-08-30 Beth Israel Deaconess Medical Center Methods and compositions for modulating leptin activity
EP0953636A3 (en) 1998-03-23 2000-03-29 Smithkline Beecham Plc Cytokine signal regulators
EP1064368A1 (en) * 1998-03-23 2001-01-03 Smithkline Beecham Plc Suppressors of cytokine signalling
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
AU4202699A (en) * 1998-05-28 1999-12-13 Incyte Pharmaceuticals, Inc. Human socs proteins
SE9803398D0 (sv) * 1998-10-06 1998-10-06 Sahltech Ab "New use"
WO2000037636A1 (en) * 1998-12-21 2000-06-29 The Walter And Eliza Hall Institute Of Medical Research Socs-box containing peptides
WO2000063357A2 (en) * 1999-04-20 2000-10-26 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
US6541244B1 (en) 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
CA2390555A1 (en) * 1999-11-16 2001-05-25 The Walter And Eliza Hall Institute Of Medical Research An animal model for studying hormone signalling and method of modulating the signalling
AU784277B2 (en) * 1999-11-16 2006-03-02 Walter And Eliza Hall Institute Of Medical Research, The An animal model for studying hormone signalling and method of modulating the signalling
WO2001079555A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2425194A1 (en) * 2000-10-09 2002-04-18 Andrew Nash Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal
GB2373502A (en) * 2000-11-08 2002-09-25 Smithkline Beecham Corp Suppressor of cytokine signalling 4 (SOCS4)
WO2002055699A2 (en) * 2000-12-14 2002-07-18 Upjohn Co Socs (suppressor of cytokine signaling)
AUPR556601A0 (en) * 2001-06-08 2001-07-12 Ludwig Institute For Cancer Research Therapeutic and diagnostic molecules - II
EP1486562A1 (en) * 2002-02-27 2004-12-15 Genox Research, Inc. Method of examining allergic disease
JP2007526000A (ja) * 2004-03-04 2007-09-13 バンダービルト ユニバーシティ サイトカイン誘導性シグナル伝達を阻害する細胞透過性ｓｏｃｓポリペプチド
JP2005312364A (ja) * 2004-04-28 2005-11-10 Mitsuo Itakura 糖尿病治療剤スクリーニング方法
US20090030179A1 (en) * 2005-02-15 2009-01-29 Toagosei Co., Ltd Antimicrobial peptide and use thereof
EP2427210A4 (en) * 2009-05-08 2012-10-24 Inst Medical W & E Hall MODULATION OF INDUCIBLE NITRIC OXIDE BINDING (INOS) TO SOCS-BOX (SSB) PEPTIDES CONTAINING SPRY DOMAINS
KR101124622B1 (ko) * 2009-10-26 2012-03-19 한국생명공학연구원 Ｓｏｃｓ２ 유전자의 발현을 조절하여 자연 살해 세포를 활성화시키는 방법
US10975149B2 (en) 2015-12-16 2021-04-13 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4420782C1 (de) * 1994-06-15 1995-08-17 Fluegge Ulf Ingo Prof Dr DNA-Sequenz, kodierend einen 2-Oxoglutarat/Malat-Translokator, Plasmide, Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
CA2143491C (en) * 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
EP0832117A1 (en) * 1995-06-05 1998-04-01 The Trustees Of Dartmouth College Ligand-stimulated gene expression
WO1998030688A1 (fr) * 1997-01-10 1998-07-16 Tadamitsu Kishimoto Nouvelle proteine de regulation de la fonction stat
WO1999003994A1 (en) * 1997-07-18 1999-01-28 Schering Corporation Suppressors of cytokine signaling socs16; related reagents

Also Published As

Publication number Publication date
CA2270171A1 (en) 1998-05-14
KR20000053017A (ko) 2000-08-25
EP0948522B1 (en) 2008-06-11
CN1253565A (zh) 2000-05-17
KR100719080B1 (ko) 2007-05-16
US20080166730A1 (en) 2008-07-10
DK0948522T3 (da) 2008-09-22
ATE398136T1 (de) 2008-07-15
KR20060053007A (ko) 2006-05-19
WO1998020023A1 (en) 1998-05-14
EP0948522A4 (en) 2001-09-19
EP1975234A2 (en) 2008-10-01
JP2009060903A (ja) 2009-03-26
NO992116D0 (no) 1999-04-30
DE69738767D1 (de) 2008-07-24
ES2308785T3 (es) 2008-12-01
CN101280305A (zh) 2008-10-08
GB2331753A (en) 1999-06-02
GB9905020D0 (en) 1999-04-28
EP0948522A1 (en) 1999-10-13
JP2001502183A (ja) 2001-02-20

Similar Documents

Publication Publication Date Title
NO992116D0 (no) Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner
ATE413386T1 (de) Ppar-gamma modulatoren
DE59005097D1 (de) Verwendung härtbarer Cycloaliphaten-Derivate in Dübelmassen.
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
DK0804163T3 (da) Forbedret fremgangsmåde til stabilisering af biologiske stoffer under tørring og efterfølgende opbevaring samt præparater deraf
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
TR199801579T2 (xx) Polimerlere dayanan b�cek �ld�r�c� bile�imler.
DE69626660T2 (de) 2-alkylpyrrolidine
ATE369755T1 (de) Verwendung von diphenylmethan-derivaten als tyrosinase-inhibitoren
ATE423788T1 (de) Neues tgf-beta-ahnliches cytokin
ATE286125T1 (de) Regulation der genexpression von bcl-2
MY107573A (en) 2,4- and 2, 5-substituted pyridine-n-oxides, processes for their preparation and their use.
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
ATE433458T1 (de) Modulatoren von ship-1
ATE139226T1 (de) Aminosulfonylharnstoff-acat-inhibitoren
DE69906568D1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
DE69431603T2 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
DE69409961T2 (de) Triarylethylenderivate zur therapeutischen verwendung
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
DK0950056T3 (da) N-(pyridinylamino)isoindoliner og beslægtede forbindelser
ES2192034T3 (es) Feniluracilos substituidos con efecto herbicida.
ATE247649T1 (de) Disubstituierte biphenyloxazoline
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer